Efficiently scaling up monoclonal antibody (mAb) manufacturing could be a problem for early-stage organizations as this section of the bioprocessing journey can pose many challenges. Builders should be assured that their course of works at bigger scales whereas being economically possible for long-term manufacturing. That’s why our Gibco media and feeds are designed with scalability in thoughts; we provide a variety of sturdy, commercially out there, and scalable protein manufacturing options to assist streamline scale-up.
A collaboration for achievement
To show the scalability of our Gibco media and feed options, we collaborated with the Centre for Biochemical Engineering and Cell Cultivation Strategies on the Zurich College of Utilized Sciences (ZHAW).
ZHAW is a number one Swiss analysis establishment with longstanding experience in life science and pharmaceutical innovation. Its Centre for Biochemical Engineering and Cell Cultivation Strategies has a robust popularity for analysis excellence in cell tradition course of growth, with greater than 20 years of bioprocessing expertise. This material experience made ZHAW a great collaborator for this undertaking.
Addressing velocity to market & scale-up challenges
Early-stage corporations usually have issue with quickly figuring out an optimum medium and feed that maximize productiveness and allow seamless scaling. Pace to market can be essential, particularly for perfusion processes the place figuring out the very best media rapidly can considerably influence manufacturing timelines. This collaboration with ZHAW aimed to sort out these challenges by evaluating the efficiency of two specialised mAb manufacturing options:
- The Gibco Environment friendly-Professional Medium and Feeds System: A next-generation resolution consisting of an modern medium and two premium feeds, designed to optimize fed-batch CHO-based bioproduction and assist a straightforward transition to medical and industrial manufacturing.
- The Gibco Excessive-Depth Perfusion (HIP) CHO Medium: A high-performing medium able to supporting excessive cell densities at low perfusion charges, developed to allow distinctive efficiency in perfusion processes whereas providing substantial ease-of-use and scalability advantages.
Maximizing mAb upstream course of effectivity
The outcomes of this examine demonstrated that each the Environment friendly-Professional system and HIP CHO Medium can assist constant, high-quality mAb manufacturing at a variety of scales, for fed-batch and perfusion-based processes respectively. This enables builders to confidently scale up their processes whereas sustaining productiveness and cost-efficiency, and assist sooner speed-to-market by rapidly figuring out optimum media options.
To seek out out extra about this collaboration and see the information for your self, go to our devoted ZHAW webpage.
Take your mAb course of to the following stage
To study extra about these merchandise go to our Gibco Efficient-Pro System and Gibco HIP-CHO Medium webpages, or get in touch with a bioprocessing representative to find how these options can profit your course of.
The submit A mAb Scale-Up Collaborative Study with the Zurich University of Applied Sciences (ZHAW) appeared first on Life in the Lab.